2.34 -0.05 (-2.09%) | 11-08 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 3.06 | 1-year : | 3.58 |
Resists | First : | 2.62 | Second : | 3.06 |
Pivot price | 2.23 | |||
Supports | First : | 2.24 | Second : | 2 |
MAs | MA(5) : | 2.38 | MA(20) : | 2.26 |
MA(100) : | 2.15 | MA(250) : | 2.21 | |
MACD | MACD : | 0 | Signal : | 0 |
%K %D | K(14,3) : | 56.3 | D(3) : | 60.1 |
RSI | RSI(14): 55.6 | |||
52-week | High : | 3.95 | Low : | 1.58 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ EQRX ] has closed below upper band by 30.7%. Bollinger Bands are 81.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 2.34 - 2.35 | 2.35 - 2.36 |
Low: | 2.31 - 2.33 | 2.33 - 2.34 |
Close: | 2.32 - 2.34 | 2.34 - 2.36 |
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Thu, 09 Nov 2023
EQRx's Acquisition by Revolution Medicines is Complete | News & Events | Goodwin - Goodwin Procter
Wed, 08 Nov 2023
Revolution Medicines and EQRx stockholders approve acquisition (NASDAQ:RVMD) - Seeking Alpha
Wed, 08 Nov 2023
Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition - Yahoo Finance
Thu, 05 Oct 2023
The unraveling of EQRx's low-cost drug dream - Fierce Biotech
Wed, 02 Aug 2023
Revolution Medicines to buy biopharmaceutical firm EQRx - Pharmaceutical Technology
Tue, 01 Aug 2023
EQRx's Affordable Drugs Strategy Ends in Acquisition by Revolution, Interested Only in Its Cash - MedCity News
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 488 (M) |
Shares Float | 320 (M) |
Held by Insiders | 11.1 (%) |
Held by Institutions | 68.2 (%) |
Shares Short | 9,960 (K) |
Shares Short P.Month | 13,370 (K) |
EPS | -0.55 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 2.41 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -13.8 % |
Return on Equity (ttm) | -20.3 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -0.63 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -330 (M) |
Levered Free Cash Flow | -159 (M) |
PE Ratio | -4.34 |
PEG Ratio | 0 |
Price to Book value | 0.97 |
Price to Sales | 0 |
Price to Cash Flow | -3.46 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |